期刊文献+
共找到28篇文章
< 1 2 >
每页显示 20 50 100
Intermittent androgen deprivation therapy in patients with prostate cancer: Connecting the dots 被引量:1
1
作者 Per-Anders Abrahamsson 《Asian Journal of Urology》 2017年第4期208-222,共15页
Intermittent androgen deprivation therapy(IADT)is now being increasingly opted by the treating physicians and patients with prostate cancer.The most common reason driving this is the availability of an off-treatment p... Intermittent androgen deprivation therapy(IADT)is now being increasingly opted by the treating physicians and patients with prostate cancer.The most common reason driving this is the availability of an off-treatment period to the patients that provides some relief from treatment-related side-effects,and reduced treatment costs.IADT may also delay the progression to castration-resistant prostate cancer.However,the use of IADT in the setting of prostate cancer has not been strongly substantiated by data from clinical trials.Multiple factors seem to contribute towards this inadequacy of supportive data for the use of IADT in patients with prostate cancer,e.g.,population characteristics(both demographic and clinical),study design,treatment regimen,on-and off-treatment criteria,duration of active treatment,endpoints,and analysis.The present review article focuses on seven clinical trials that evaluated the efficacy of IADT vs.continuous androgen deprivation therapy for the treatment of prostate cancer.The results from these clinical trials have been discussed in light of the factors that may impact the treatment outcomes,especially the disease(tumor)burden.Based on evidence,potential candidate population for IADT has been suggested along with recommendations for the use of IADT in patients with prostate cancer. 展开更多
关键词 Continuous androgen deprivation therapy intermittent androgen deprivation therapy Prostate cancer Study designs and outcomes Tumor burden
下载PDF
Improving intermittent androgen deprivation therapy: lessons learned from basic and translational research 被引量:2
2
作者 Rahul A Parikh Laura E Pascal +1 位作者 Benjamin J Davieses Zhou Wang 《Asian Journal of Andrology》 SCIE CAS CSCD 2014年第4期505-510,共6页
Intermittent androgen deprivation therapy (IADT) is an alternative to continuous androgen deprivation therapy (ADT) in prostate cancer patients with nonmetastatic disease. ADT is associated with numerous side effe... Intermittent androgen deprivation therapy (IADT) is an alternative to continuous androgen deprivation therapy (ADT) in prostate cancer patients with nonmetastatic disease. ADT is associated with numerous side effects such as hot flashes, sexual dysfunction, anemia, fatigue, loss of muscle mass, osteoporosis, metabolic syndrome and premature cardiovascular disease. IADT was developed with the intention of improving the quality of life and to delay progression of prostate cancer to castration resistance. The benefits of slightly improved quality of life by IADT compared to ADT were demonstrated in multiple clinical trials. IADT was noted to be noninferior to ADT in patients with biochemical recurrence of prostate cancer but in studies performed in patients with metastatic prostate cancer, the results were inconclusive. Our recent studies suggested that the administration of 5 alpha-reductase inhibitors during the off-cycle of IADT can significantly prolong the survival of mice bearing androgen-sensitive prostate tumors when off-cycle duration was short. This review discusses the survival benefit of 5 alpha-reductase inhibition in IADT in animal models and the potential translation of this finding into clinic. 展开更多
关键词 5 alpha-reductase inhibitor androgen-responsive genes intermittent androgen deprivation therapy (IADT) prostatecancer TESTOSTERONE
下载PDF
Salvage treatments for prostate-specific antigen relapse of cT3N0M0 prostatic adenocarcinoma after radical prostatectomy combined with neoadjuvant androgen deprivation
3
作者 Lufang Zhang Dongliang Pan +2 位作者 Ludong Liu Yunjiang Zang Ningchen Li 《Oncology and Translational Medicine》 CAS 2020年第6期272-276,共5页
Objective The aim of the study was to evaluate the efficiency of salvage treatments for prostate specific antigen(PSA)relapse of cT3N0M0 prostatic adenocarcinoma(PCa)after radical prostatectomy(RP)combined with neoadj... Objective The aim of the study was to evaluate the efficiency of salvage treatments for prostate specific antigen(PSA)relapse of cT3N0M0 prostatic adenocarcinoma(PCa)after radical prostatectomy(RP)combined with neoadjuvant androgen deprivation(ADT).Methods A total of 332 patients with cT3N0M0 PCa were enrolled in the prospective study and received RP and pelvic lymph node dissection with neoadjuvant ADT for 3 months.All patients with PSA relapse were treated with salvage external beam radiation therapy(RT)and ADT for 6 months.Results The 5-year postoperative PSA relapse rate was 40.96%(136/332).The patients have been divided into the PSA relapse and PSA relapse-free groups in order to compare patient characteristics.The ratio of patients with Gleason score≥8 and positive surgical margin in the PSA relapse group were significantly higher than those of in the PSA relapse-free group(P=0.01).The mean duration between the start of operative treatment and PSA relapse was 31 months.Salvage treatment to all 136 PSA relapse patients led to favorable outcomes.PSA relapse was not observed after salvage treatment by the end of follow-up.The 5-year overall survival rates of the PSA relapse and PSA relapse-free groups were 94.9%and 93.9%,respectively.Conclusion In pursuit of curative treatment,our study showed that RP combined with neoadjuvant ADT is an aggressive multimodality strategy associated with lower PSA relapse and better survival outcomes for stage cT3N0M0 PCa patients.Patients with PSA relapse after RP may benefit from early aggressive salvage RT combined with short-term ADT. 展开更多
关键词 prostatic adenocarcinoma(PCa) radical prostatectomy(RP) neoadjuvant androgen deprivation(ADT) external beam radiation therapy salvage treatment prostate specific antigen(PSA)relapse
下载PDF
Treatment-induced neuroendocrine prostate cancer and de novo neuroendocrine prostate cancer:Identification,prognosis and survival,genetic and epigenetic factors
4
作者 Mohamed Wishahi 《World Journal of Clinical Cases》 SCIE 2024年第13期2143-2146,共4页
Neuroendocrine prostate cancer(NEPC)shows an aggressive behavior compared to prostate cancer(PCa),also known as prostate adenocarcinoma.Scanty foci in PCa can harbor genetic alternation that can arise in a heterogenei... Neuroendocrine prostate cancer(NEPC)shows an aggressive behavior compared to prostate cancer(PCa),also known as prostate adenocarcinoma.Scanty foci in PCa can harbor genetic alternation that can arise in a heterogeneity of prostate cancer.NEPC may arise de novo or develop following androgen deprivation therapy(ADT).NEPC that arise following ADT has the nomenclature“treatmentemerging/induced NEPC(t-NEPC)”.t-NEPC would be anticipated in castration resistant prostate cancer(CRPC)and metastatic PCa.t-NEPC is characterized by low or absent androgen receptor(AR)expression,independence of AR signaling,and gain of neuroendocrine phenotype.t-NEPC is an aggressive metastatic tumor,develops from PCa in response to drug induced ADT,and shows very short response to conventional therapy.t-NEPC occurs in 10%-17%of patients with CRPC.De novo NEPC is rare and is accounting for less than 2%of all PCa.The molecular mechanisms underlying the trans-differentiation from CRPC to t-NEPC are not fully elucidated.Sphingosine kinase 1 plays a significant role in t-NEPC development.Although neuroendocrine markers:Synaptophysin,chromogranin A,and insulinoma associated protein 1(INSM1)are expressed in t-NEPC,they are non-specific for diagnosis,prognosis,and follow-up of therapy.t-NEPC shows enriched genomic alteration in tumor protein P53(TP53)and retinoblastoma 1(RB1).There are evidences suggest that t-NEPC might develop through epigenetic evolution.There are genomic,epigenetic,and transcriptional alterations that are reported to be involved in development of t-NEPC.Knock-outs of TP53 and RB1 were found to contribute in development of t-NEPC.PCa is resistant to immunotherapy,and at present there are running trials to approach immunotherapy for PCa,CRPC,and t-NEPC. 展开更多
关键词 Prostate cancer Neuroendocrine carcinoma treatment induced neuroendocrine prostate cancer androgen deprivation therapy Genetic and epigenetic factors Castration resistant prostate cancer De novo neuroendocrine prostate cancer
下载PDF
Mathematically modelling and controlling prostate cancer under intermittent hormone therapy
5
作者 Yoshito Hirata Gouhei Tanaka +1 位作者 Nicholas Bruchovsky Kazuyuki Aihara 《Asian Journal of Andrology》 SCIE CAS CSCD 2012年第2期270-277,共8页
In this review, we summarize our recently developed mathematical models that predict the effects of intermittent androgen suppression therapy on prostate cancer (PCa). Although hormone therapy for PCa shows remarkab... In this review, we summarize our recently developed mathematical models that predict the effects of intermittent androgen suppression therapy on prostate cancer (PCa). Although hormone therapy for PCa shows remarkable results at the beginning of treatment, cancer cells frequently acquire the ability to grow without androgens during long-term therapy, resulting in an eventual relapse. To circumvent hormone resistance, intermittent androgen suppression was investigated as an alternative treatment option. However, at the present time, it is not possible to select an optimal schedule of on- and off-treatment cycles for any given patient. In addition, clinical trials have revealed that intermittent androgen suppression is effective for some patients but not for others. To resolve these two problems, we have developed mathematical models for PCa under intermittent androgen suppression. The mathematical models not only explain the mechanisms of intermittent androgen suppression but also provide an optimal treatment schedule for the on- and off-treatment periods. 展开更多
关键词 DIAGNOSIS intermittent androgen suppression mathematical models personalized treatment schedule PROGNOSIS prostate cancer
下载PDF
Prostate Cancer Disease Characteristics at the Time of Diagnosis and Initial Treatment Offered in a Tertiary Hospital at Ouagadougou (Burkina Faso)
6
作者 Fasnéwindé Aristide Kaboré Barnabé Zango +5 位作者 Timothé Kambou Aimé Sosthène Ouédraogo Aboubacar Bambara Clotaire Yaméogo Brahima Kirakoya Olga Lompo 《Open Journal of Urology》 2014年第1期7-12,共6页
Objectives: to describe the characteristics of newly diagnosed prostate cancer (PCa) and the initial treatments offered to patients in the most important urological center of Burkina Faso. Methods: We analyzed the dat... Objectives: to describe the characteristics of newly diagnosed prostate cancer (PCa) and the initial treatments offered to patients in the most important urological center of Burkina Faso. Methods: We analyzed the data of a cohort of 168 consecutive patients with no prior history of PCa between January 2009 and December 2012. Diagnosis of PCa was based on histological analysis of transrectal prostate biopsies. Patient and disease characteristics and the initial treatment offered were taken in account. Results: The mean age at presentation was 68.59 ± 9.41 years (range 30 to 95 years). There was a 3.6-fold increase in the incidence of PCa through the four years of the study. The mean duration of symptoms prior to presentation was 11.6 ± 10.9 months. The majority of cases (86.9%) were presented as locally advanced or metastatic disease. Androgen deprivation therapy (ADT) was the first therapeutic option for 121 patients (72%) and 73 patients (43.4%) underwent ADT through bilateral orchiectomy. Only 3 patients (1.78%) underwent radical prostatectomy. Conclusion: An increase in the diagnosis of PCa in our country was observed in this study. The diagnosis of prostate cancer was usually tardive in Burkina Faso. Treatment often involves surgical ADT for socioeconomic reasons. 展开更多
关键词 Prostrate Cancer PSA PRESENTING SYMPTOMS treatment androgen deprivation Therapy Burkina Faso
下载PDF
Prostate cancer genotyping for risk stratification and precision treatment
7
作者 Ashish A.Kumar 《Current Urology》 2024年第2期87-97,共11页
Prostate cancer(PC)is the most frequently diagnosed cancer and second leading cause of cancer-related deaths in men.It is heterogeneous,as is evident from the wide spectrum of therapeutic approaches.Most patients with... Prostate cancer(PC)is the most frequently diagnosed cancer and second leading cause of cancer-related deaths in men.It is heterogeneous,as is evident from the wide spectrum of therapeutic approaches.Most patients with PC are initially responsive to androgen deprivation therapy;however,themajority of cases are either hormone-sensitive PC or castration-resistant PC.Current therapeutic protocols follow the evolution of PC,a continuously progressive process involving a combination of widespread genomic alterations.These genomic alterations are either hereditary germline mutations,such as mutations in BRCA2,or specific only to tumor cells(somatic).Tumor-specific genomic spectra include genomic structural rearrangements,canonical androgen response genes,andmany other specific genes such as TMPRSS2-ERG fusion,SPOP/FOXA1,TP53/RB1/PTEN,andBRCA2.New evidence indicates the involvement of signaling pathways including PI3K,WNT/β-catenin,SRC,and IL-6/STAT,which have been shown to promote epithelial-mesenchymal transition cancer stem cell–like features/stemness,and neuroendocrine differentiation in PC.Over the last decade,our understanding of the genotype-phenotype relationships has been enhanced considerably.The genetic background of PC related to canonical genetic alterations and signaling pathway activation genes has shed more insight into the molecular subtype and disease landscape,resulting in a more flexible role of individual therapies targeting diverse genotypes and phenotypes. 展开更多
关键词 Prostate cancer Prostate cancer treatment Prostate cancer genomics Hereditary prostate cancer androgen deprivation therapy Hormone sensitive prostate cancer Kinase signaling
原文传递
两种方法联合间歇性雄激素抑制治疗中晚期前列腺癌的疗效观察 被引量:12
8
作者 吴舟 吴宏 +2 位作者 田焕书 叶木石 黄兴端 《重庆医学》 CAS CSCD 北大核心 2012年第2期138-139,共2页
目的观察经尿道等离子前列腺电切术(TUPKP)和睾丸切除术联合间歇性雄激素抑制(IAD)治疗中晚期前列腺癌(Pca)的疗效。方法 40例中晚期Pca患者行TUPKP治疗并且行睾丸切除术和IAD治疗。结果 6个月后,国际前列腺症状评分(IPSS)、生活质量评... 目的观察经尿道等离子前列腺电切术(TUPKP)和睾丸切除术联合间歇性雄激素抑制(IAD)治疗中晚期前列腺癌(Pca)的疗效。方法 40例中晚期Pca患者行TUPKP治疗并且行睾丸切除术和IAD治疗。结果 6个月后,国际前列腺症状评分(IPSS)、生活质量评分(QOL)、最大尿流率(MFR)、残余尿量(RV)、前列腺特异抗原(PSA)、前列腺体积等与术前比较差异有统计学意义(P<0.01)。结论 TUPKP和睾丸切除联合IAD治疗中晚期Pca的疗效确切,明显提高患者生活质量,值得临床推广应用。 展开更多
关键词 前列腺肿瘤 经尿道前列腺切除术 睾丸切除术 间歇性内分泌治疗 持续性雄激素阻断
下载PDF
前列腺癌内分泌治疗方法研究及预后分析 被引量:26
9
作者 黄宝星 宿恒川 +1 位作者 曹万里 孙福康 《中华男科学杂志》 CAS CSCD 2013年第9期815-819,共5页
目的:探究延长前列腺癌患者进展为激素非依赖性前列腺癌(AIPC)时间的内分泌治疗方法。方法:经直肠活检穿刺证实前列腺癌患者93例,分为3组:22例患者接受双侧睾丸切除加比卡鲁胺联合治疗,行持续性全雄激素阻断(CAD);71例患者行间歇性内分... 目的:探究延长前列腺癌患者进展为激素非依赖性前列腺癌(AIPC)时间的内分泌治疗方法。方法:经直肠活检穿刺证实前列腺癌患者93例,分为3组:22例患者接受双侧睾丸切除加比卡鲁胺联合治疗,行持续性全雄激素阻断(CAD);71例患者行间歇性内分泌治疗方法,其中29例患者行标准间歇性内分泌治疗(IAD),42例患者行改良型间歇性内分泌治疗;两组治疗期用戈舍瑞林或亮丙瑞林联合比卡鲁胺的用药方案,行雄激素最大阻断(MAB),当患者血清PSA下降至<0.2μg/L,维持用药3个月。进入间歇期,IAD组停药,改良型IAD组停用促黄体生成激素释放激素类似物(LHRH-a),但维持使用比卡鲁胺,两组在间歇期内出现PSA持续升高,且大于4μg/L时,则再次启用MAB,直至患者进展为AIPC。比较CAD、IAD及改良型IAD 3组患者疾病随访时间、疾病进展时间及治疗周期。结果:3组患者人口学特征、基线资料及随访时间相似,中位进展时间分别为(26.50±4.15)月、(30.00±7.83)月和(34.93±5.08)月,CAD与标准IAD组比较差异无统计学意义(P=0.143),改良型IAD组与CAD及IAD组比较差异有统计学意义(P=0.001,0.032)。Kaplan-Meier生存分析显示,改良组中位进展时间明显长于标准IAD治疗组(P=0.01)。标准IAD与改良型IAD组平均治疗周期分别为(16.13±3.33)月和(19.58±4.30)月,两组第1治疗周期间歇期分别为(9.6±3.2)月和(14.2±3.7)月,组间比较差异显著(P=0.001)。结论:与CAD和标准IAD比较,改良型IAD可显著延长前列腺癌患者进展为AIPC的时间。 展开更多
关键词 前列腺癌 持续性雄激素阻断 间歇性雄激素阻断 激素非依赖性前列腺癌
下载PDF
间断雄激素阻断治疗进展期前列腺癌之8年临床经验分析 被引量:7
10
作者 邵强 张峰波 +2 位作者 朱晓东 杜源 田野 《中华男科学杂志》 CAS CSCD 2013年第1期44-48,共5页
目的:探讨间断雄激素阻断法(IAD)治疗进展期前列腺癌的安全性及用药周期特征。方法:178例进展期前列腺癌患者依据临床分期分为A(T3-4N0M0)、B(TXN1M0)和C(TXNXM1)3组。所有患者一经确诊即给予最大雄激素阻断治疗至少6个月,至PSA≤0.2μ... 目的:探讨间断雄激素阻断法(IAD)治疗进展期前列腺癌的安全性及用药周期特征。方法:178例进展期前列腺癌患者依据临床分期分为A(T3-4N0M0)、B(TXN1M0)和C(TXNXM1)3组。所有患者一经确诊即给予最大雄激素阻断治疗至少6个月,至PSA≤0.2μg/L后维持3个月后,暂停雄激素阻断治疗,进入间歇期(Off-Period);当PSA>4μg/L时,进入用药期(On-Period),直至PSA再次达到0.2μg/L以下停药。分别记录各组患者年龄、初始PSA值、Gleason评分以及治疗期间每个周期的用药期及停药期时间、PSA水平及肿瘤进展时间。结果:A、B、C 3组患者初始PSA水平分别为(27.5±14.6)、(43.4±21.8)、(62.8±44.6)μg/L(P<0.01);平均随访时间分别为(38.4±9.6)、(33.1±14.0)、(28.3±14.3)个月;开始治疗至出现肿瘤进展的平均时间为(37.4±6.6)、(27.4±10.2)、(16.6±4.4)个月。A组患者平均间歇期时间显著长于B组和C组,C组患者On/Off值显著大于A组,且完成的IAD周期数显著少于A组(P<0.01)。19例A组患者完成5个治疗周期。C组患者最多完成3个治疗周期即出现PSA及肿瘤进展。2例A组患者死于心血管事件;B组患者6例死亡,其中1例死于前列腺癌转移;C组36例死亡,其中21例死于转移性前列腺癌。结论:与存在远处转移的前列腺癌患者相比,局部进展性前列腺癌患者采用间断雄激素阻断治疗可有效缓解肿瘤进展,减少IAD治疗的相关不良反应,提高患者生活质量。 展开更多
关键词 前列腺癌 去势 雄激素阻断 间断治疗
下载PDF
晚期前列腺癌不同雄激素剥夺治疗方式与继发糖尿病和糖耐量异常风险的相关性研究 被引量:5
11
作者 曾胜 李卓平 +3 位作者 李伟 卜威震 刘鹏 马志方 《中华男科学杂志》 CAS CSCD 北大核心 2017年第7期598-602,共5页
目的:探讨晚期前列腺癌间歇性雄激素剥夺治疗(IADT)和持续性雄激素剥夺治疗(CADT)两种不同方式与继发糖尿病(DM)和糖耐量异常(IGT)风险的相关性。方法:对2013年1月至2015年12月于我院进行雄激素剥夺治疗(ADT)的PCa患者进行回顾性病例对... 目的:探讨晚期前列腺癌间歇性雄激素剥夺治疗(IADT)和持续性雄激素剥夺治疗(CADT)两种不同方式与继发糖尿病(DM)和糖耐量异常(IGT)风险的相关性。方法:对2013年1月至2015年12月于我院进行雄激素剥夺治疗(ADT)的PCa患者进行回顾性病例对照研究。通过监测患者空腹血糖、餐后2 h血糖及口服糖耐量试验,结合患者相关临床症状,对IADT和CADT引起DM和IGT的风险进行统计学分析,并分析组内体质量指数(BMI)、高血压、吸烟、饮酒等因素与继发性DM和IGT的关系。结果:IADT组53例(46.5%),平均(69.1±4.3)岁;CADT组61例(53.5%),平均(70.2±5.7)岁,两组在临床特点方面均无明显差异(P均>0.05);IADT组BMI、高血压、吸烟、饮酒等因素对DM、IGT的发生均无明显影响(P均>0.05),CADT组BMI、高血压、吸烟、饮酒因素对DM、IGT的发生均无明显影响(P均>0.05);IADT组与CADT组比较,DM的发生无统计学意义(P=0.64);但IGT的发生有统计学意义(P=0.03)。结论:IADT与CADT比较,PCa患者的IGT发生风险更低,安全性更高。 展开更多
关键词 前列腺癌 间歇性雄激素剥夺治疗 持续性雄激素剥夺治疗 糖尿病 糖耐量异常
下载PDF
晚期前列腺癌的间歇性与持续性雄激素阻断治疗选择 被引量:7
12
作者 钟山 王先进 +2 位作者 许天源 夏磊磊 沈周俊 《现代泌尿外科杂志》 CAS 2015年第11期823-827,共5页
在晚期或复发性前列腺癌的治疗中,间歇性雄激素阻断(IAD)治疗正逐渐成为持续性雄激素阻断治疗(CAD)的替代选择。尽管在转移性前列腺癌患者中,IAD的优势并未明确,但对于其他无转移的晚期前列腺癌患者,该方法可作为标准治疗选择。本文介绍... 在晚期或复发性前列腺癌的治疗中,间歇性雄激素阻断(IAD)治疗正逐渐成为持续性雄激素阻断治疗(CAD)的替代选择。尽管在转移性前列腺癌患者中,IAD的优势并未明确,但对于其他无转移的晚期前列腺癌患者,该方法可作为标准治疗选择。本文介绍了IAD应用相关的问题,包括患者选择、治疗和随访周期。 展开更多
关键词 间歇性雄激素阻断 持续性雄激素阻断 前列腺肿瘤
下载PDF
间歇性与持续性雄激素阻断治疗晚期前列腺癌疗效比较 被引量:7
13
作者 吴松 赖海标 +8 位作者 钟亮 黄智峰 曾晔 李森 赖伟业 郑东祥 刘毅豪 唐荣志 黄新凯 《中国医药科学》 2014年第7期56-58,共3页
目的:比较间歇性与持续性雄激素阻断治疗晚期前列腺癌的疗效以及治疗产生的副作用。方法选取我科2012年1月-2013年1月收治的晚期前列腺癌患者76例,分为观察组(38例)及对照组(38例)。观察组38例行间歇性雄激素阻断治疗即药物去势... 目的:比较间歇性与持续性雄激素阻断治疗晚期前列腺癌的疗效以及治疗产生的副作用。方法选取我科2012年1月-2013年1月收治的晚期前列腺癌患者76例,分为观察组(38例)及对照组(38例)。观察组38例行间歇性雄激素阻断治疗即药物去势加抗雄激素药物,对照组38例行持续性雄激素阻断治疗即手术去势加抗雄激素药物。比较两组患者的副反应发生率及治疗后的生活质量。结果观察组38例患者发生潮热症状者13例(34.21%)、乳房胀痛者12例(31.58%)。对照组23例患者发生潮热症状者26例(68.42%)、乳房胀痛者25例(65.79%)。比较两组潮热症状及乳房胀痛的发生率差异均有统计学意义(P<0.05)。两组患者治疗后,观察组患者在肠道症状、性功能、尿路症状、骨痛、治疗相关症状方面都较对照组有明显的改善,生活质量大大提高,两组对比差异有统计学意义(P<0.01)。结论间歇性联合雄激素阻断治疗可以明显降低患者治疗的副作用并且增加治疗后的生活质量,是晚期前列腺癌患者行雄激素阻断治疗的首选方案。 展开更多
关键词 前列腺癌 间歇性雄激素阻断 持续性雄激素阻断
下载PDF
2019 EAU-EANM-ESTRO-ESUR-SIOG转移性前列腺癌指南解读 被引量:6
14
作者 李晋 陈波 +4 位作者 陈泽昱 曹德宏 柳良仁 魏强 董强 《西部医学》 2020年第2期160-165,共6页
国内目前研究显示在初诊为前列腺癌的患者中转移性前列腺癌(mPC)患者大约占54%,其五年生存率相比非转移性前列腺癌低了两倍,同时mPC对药物耐药逐年增加,使优化其治疗选择彰显得更为重要。欧洲泌尿外科协会联合欧洲放射肿瘤学会、欧洲泌... 国内目前研究显示在初诊为前列腺癌的患者中转移性前列腺癌(mPC)患者大约占54%,其五年生存率相比非转移性前列腺癌低了两倍,同时mPC对药物耐药逐年增加,使优化其治疗选择彰显得更为重要。欧洲泌尿外科协会联合欧洲放射肿瘤学会、欧洲泌尿生殖放射学会与国际老年肿瘤学会(EAU-ESTRO-ESUR-SIOG)根据各大临床试验与基础研究每年制定了mPC的治疗指南,用于指导mPC的临床治疗及疾病监测,受到广大专家学者的广泛欢迎。因此,为了更好推广mPC的诊治指南,规范mPC的治疗,本文就2019年EAU-EANM-ESTRO-ESUR-SIOG指南中mPC的治疗更新、治疗检测、治疗时机进行解读。 展开更多
关键词 转移性前列腺癌 一线治疗 内分泌治疗 指南 指南解读
下载PDF
晚期前列腺癌的间歇雄激素阻断治疗 被引量:2
15
作者 张晓文 姚茂银 +5 位作者 杨建军 苏昀 苑章 柳靖 杨关天 霍明东 《东南大学学报(医学版)》 CAS 2006年第6期458-460,共3页
目的:了解间歇雄激素阻断(IAD)方法对晚期前列腺癌的治疗作用。方法:回顾性分析21例晚期前列腺癌病人,应用药物诺雷德去势加氟他胺(甲组)或康士得IAD方法(乙组)治疗的结果。结果:21例患者经IAD治疗后,绝大多数取得了较好的疗效。甲组3... 目的:了解间歇雄激素阻断(IAD)方法对晚期前列腺癌的治疗作用。方法:回顾性分析21例晚期前列腺癌病人,应用药物诺雷德去势加氟他胺(甲组)或康士得IAD方法(乙组)治疗的结果。结果:21例患者经IAD治疗后,绝大多数取得了较好的疗效。甲组3年生存率为72.7%,乙组为80.0%,总3年生存率为76.2%。治疗间歇中减少了抗激素药物的应用,从而明显减少了潮红、体重增加及忧郁等内分泌治疗的副作用。结论:IAD治疗能推迟雄激素依赖性前列腺癌细胞向非依赖性细胞的转化,同时减少药物用量和毒副作用,明显改善患者的生活质量并降低治疗费用。 展开更多
关键词 前列腺癌 间歇雄激素阻断 药物去势
下载PDF
间歇性雄激素阻断治疗晚期前列腺癌效果观察 被引量:5
16
作者 吴洋 胡云飞 +1 位作者 胡俊丹 孙刚 《临床外科杂志》 2008年第7期474-476,共3页
目的评价间歇性雄激素阻断治疗晚期前列腺癌的可行性及优点。方法选取晚期前列腺癌患者59例,随机分为2组。给予间歇性雄激素阻断治疗30例(A组),给予持续雄激素阻断治疗29例(B组),观察两组患者的疾病进展及治疗期间副反应的发生情况,比... 目的评价间歇性雄激素阻断治疗晚期前列腺癌的可行性及优点。方法选取晚期前列腺癌患者59例,随机分为2组。给予间歇性雄激素阻断治疗30例(A组),给予持续雄激素阻断治疗29例(B组),观察两组患者的疾病进展及治疗期间副反应的发生情况,比较两种方法的治疗效果。结果A组患者平均随访26个月,B组患者平均随访27个月,两组患者疾病进展情况未见明显差异。A组患者副反应低于B组患者且能在治疗间歇期得到缓解。结论间歇性雄激素阻断治疗方法可行,能够减少患者治疗的副反应,提高患者生活质量。 展开更多
关键词 前列腺肿瘤 间歇性雄激素阻断治疗 副反应
下载PDF
基于认知行为疗法的院外护理干预对单纯雄激素剥夺治疗的前列腺癌患者影响 被引量:1
17
作者 冯瑶 李海燕 +4 位作者 黄航 陈建霞 张海微 吴蓉蓉 江海红 《中国现代医生》 2021年第20期175-179,共5页
目的研究基于认知行为疗法(CBT)的院外护理干预对单纯雄激素剥夺治疗的老年前列腺癌患者跌倒风险的影响,为提高此类患者的护理质量提供临床依据。方法将2018年10月至2019年10月我院符合纳入标准的120例诊断为前列腺癌并行单纯雄激素剥... 目的研究基于认知行为疗法(CBT)的院外护理干预对单纯雄激素剥夺治疗的老年前列腺癌患者跌倒风险的影响,为提高此类患者的护理质量提供临床依据。方法将2018年10月至2019年10月我院符合纳入标准的120例诊断为前列腺癌并行单纯雄激素剥夺治疗的患者,随机分成观察组与对照组,每组各60例,对照组患者给予常规护理;观察组患者在常规护理基础上,实施基于CBT的院外护理干预。出院12周后,采用Herth希望量表了解两组患者的希望水平。采用Berg平衡量表观察两组患者的平衡情况以判断其跌倒风险;采用生活质量评价量表SF-36了解两组患者的生活质量情况;采用自制满意度问卷调查表比较两组患者对护理质量的满意度。结果观察组患者的希望水平、平衡功能、生活质量评分及对护理工作的满意度均高于对照组,差异有统计学意义(P<0.05)。结论对离院后单纯雄激素剥夺治疗的老年前列腺癌患者进行基于CBT的院外护理干预,可以减少患者的负面情绪,提高希望水平和生活质量,有效降低跌倒的发生风险,提高患者对护理质量的满意度,值得在临床工作中推广应用。 展开更多
关键词 认知疗法 护理 前列腺癌 雄激素剥夺治疗
下载PDF
联合间歇性内分泌与 ^(125)I放射性粒子植入术治疗局部晚期前列腺癌(附20例报告) 被引量:5
18
作者 李宇 黄毅 《中国肿瘤临床》 CAS CSCD 北大核心 2009年第10期544-547,共4页
目的:探讨联合^(125)I放射性粒子植入术和间歇性内分泌治疗局部进展期前列腺癌的临床价值。方法:前列腺癌患者20例,年龄52~80岁,中位年龄74岁,PSA:6.83~643.8ng/mL,Gleason Score:7~9分,临床分期T3N0M0。连续硬膜外麻醉,截石位,直肠... 目的:探讨联合^(125)I放射性粒子植入术和间歇性内分泌治疗局部进展期前列腺癌的临床价值。方法:前列腺癌患者20例,年龄52~80岁,中位年龄74岁,PSA:6.83~643.8ng/mL,Gleason Score:7~9分,临床分期T3N0M0。连续硬膜外麻醉,截石位,直肠超声从前列腺基底到尖部进行扫描,图像传送至计算机计划系统进行三维重建和术中计划,根据计划行直肠超声引导下经会阴^(125)I放射性粒子植入术,术后结合雄激素全阻断疗法。当PSA达到0ng/mL,并稳定2个月后停止内分泌治疗,当PSA连续3次上升,则重新开始内分泌治疗。结果:所有患者手术均顺利,术中使用穿刺针26~36根,植入粒子57~99粒,平均73粒。术后随访8~51个月,平均22月。1例术后16个月发生骨转移,1例术后22个月死亡。术后3~5个月所有患者的PSA都降到正常范围,其中3例PSA未达到0ng/mL,未停药。4例术后5~26个月,出现PSA反弹,再次用药3~5个月PSA值达到13ng/mL。目前12例未出现PSA反弹,第一周期脱离治疗时间2~44个月,平均16.9个月。近期出现的并发症有轻至中度尿路刺激症30%(6/20),急性尿潴留50%(1/20),直肠刺激症和血便25%(5/20),多数患者症状随访1年后缓解。目前18例患者的PSA值在0~1.2ng/mL之间,其中17患者PSA≤0.17ng/mL。结论:对于局部晚期前列腺癌,^(125)I放射粒子植入术结合间歇性内分泌是一种安全有效的治疗方法。 展开更多
关键词 前列腺癌 粒子植入术 间歇性内分泌治疗
下载PDF
前列腺癌患者不同治疗方法疗效分析 被引量:3
19
作者 毛东方 黄随富 《中国当代医药》 2012年第22期34-34,36,共2页
目的探讨不同治疗方法对前列腺癌的治疗效果。方法观察本院收治的前列腺癌患者使用不同治疗方法的治疗效果,观察组39例采用去势手术治疗联合根治术治疗,对照组28例采用根治术治疗。结果观察组和对照组治疗前后前列腺症状评分(IPSS)差异... 目的探讨不同治疗方法对前列腺癌的治疗效果。方法观察本院收治的前列腺癌患者使用不同治疗方法的治疗效果,观察组39例采用去势手术治疗联合根治术治疗,对照组28例采用根治术治疗。结果观察组和对照组治疗前后前列腺症状评分(IPSS)差异有统计学意义(P值分别为0.01和0.01),观察组3年、5年生存率较对照组高,差异有统计学意义(P<0.05)。结论根治术联合去势治疗术结合治疗前列腺癌有利于提高患者生存时间和前列腺功能。 展开更多
关键词 前列腺癌 去势手术治疗 根治术治疗 疗效
下载PDF
不同雄激素阻断方案治疗晚期前列腺癌患者疗效的临床研究
20
作者 罗怀景 张婷婷 +2 位作者 董兴模 林超禄 余丰 《中国临床药理学杂志》 CAS CSCD 北大核心 2024年第4期519-523,共5页
目的 对比间歇性雄激素阻断(IAD)治疗与持续性雄激素阻断(CAD)治疗晚期前列腺癌患者的效果及对预后影响。方法 将晚期前列腺癌患者按照队列法分为试验组(86例)和对照组(62例)。试验组采取IAD方案,即皮下注射戈舍瑞林3.6 mg(每28 d注射1... 目的 对比间歇性雄激素阻断(IAD)治疗与持续性雄激素阻断(CAD)治疗晚期前列腺癌患者的效果及对预后影响。方法 将晚期前列腺癌患者按照队列法分为试验组(86例)和对照组(62例)。试验组采取IAD方案,即皮下注射戈舍瑞林3.6 mg(每28 d注射1次),联合口服氟他胺250 mg(tid),或联合比卡鲁胺口服,每次50 mg(qd);对照组采取CAD方案治疗,即双侧睾丸切除术联合持续氟他胺或比卡鲁胺口服,用法用量同试验组。2组观察随访时间均≥9个月。比较治疗后2组疗效、血清总睾酮(TT)、前列腺特异性抗原(PSA)及血管内皮生长因子(VEGF)水平,评价患者治疗药物不良反应、生存质量[前列腺癌治疗与功能评价(FACT-P)问卷]及疾病进展情况。结果 治疗后9个月,试验组和对照组客观缓解率(ORR)分别为30.99%(22例/71例)和29.09%(16例/55例),疾病进展率(DCR)分别为71.83%(51例/71例)和69.09%(38例/55例),差异均无统计学意义(均P>0.05)。试验组和对照组血清TT分别为(25.53±9.44)和(22.51±8.28)ng·dL^(-1),PSA分别为(4.48±1.02)和(4.32±0.95)ng·mL^(-1),VEGF分别为(121.03±35.26)和(118.65±33.42)pg·mL^(-1),差异均无统计学意义(均P>0.05);试验组和对照组潮热发生率分别为21.13%和56.36%,乳房肿痛分别为16.90%和34.55%,骨质疏松分别为8.45%和25.45%,差异均有统计学意义(均P<0.05);试验组和对照组FACT-P中身体状况得分分别为(24.15±4.22)和(20.28±3.71)分,生活状况得分分别为(20.28±2.94)和(17.81±2.84)分,前列腺特异性(PCS)模块得分分别为(33.21±6.32)和(28.42±5.43)分,差异均有统计学意义(均P<0.05)。试验组和对照组的累计无进展生存率分别为61.97%和58.18%,差异无统计学意义(P>0.05)。结论 IAD与CAD治疗晚期前列腺癌疗效及对患者预后影响相当,但前者治疗药物不良反应更少,有助于提高患者生存质量。 展开更多
关键词 前列腺癌 间歇性雄激素阻断 持续性雄激素阻断 安全性 预后
原文传递
上一页 1 2 下一页 到第
使用帮助 返回顶部